double-blind placebo-controlled trial and its non-randomised non-blind extension phase Lancet 2017 162 Schectman G, Hiatt J Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals Am J Med 1996;100(2):197–204 163 Parizo J, Sarraju A, Knowles JW Novel therapies for familial hypercholesterolemia Curr Treat Options Cardiovasc Med 2016;18(11):64 164 Sabatine MS, Giugliano RP, Wiviott SD, et al Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med 2015;372(16):1500–1509 165 Robinson JG, Farnier M, Krempf M, et al Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 2015;372(16):1489–1499 166 Blom DJ, Hala T, Bolognese M, et al A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 2014;370(19):1809–1819 167 Sabatine MS, Giugliano RP, Keech AC, et al Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med 2017;376(18):1713–1722 168 Raal FJ, Stein EA, Dufour R, et al PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, doubleblind, placebo-controlled trial Lancet 2015;385(9965):331–340 169 Kastelein JJ, Ginsberg HN, Langslet G, et al ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 2015;36(43):2996–3003 170 Raal FJ, Honarpour N, Blom DJ, et al Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 2015;385(9965):341–350 171 Folsom AR, Burke GL, Ballew C, et al Relation of body fatness and its distribution to cardiovascular risk factors in young blacks and whites The role of insulin Am J Epidemiol 1989;130(5):911–924 172 Burns TL, Moll PP, Lauer RM Increased familial cardiovascular mortality in obese schoolchildren: the Muscatine Ponderosity Family Study Pediatrics 1992;89(2):262–268 173 Sinaiko AR, Donahue RP, Jacobs DR Jr, Prineas RJ Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults The Minneapolis Children's Blood Pressure Study Circulation 1999;99(11):1471–1476 174 Morrison JA, Friedman LA, Gray-McGuire C Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study Pediatrics 2007;120(2):340–345 175 Grundy SM, Cleeman JI, Daniels SR, et al Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 2005;112(17):2735–2752 176 Ford ES Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the u.s Diabetes Care 2005;28(11):2745–2749 177 Smoak CG, Burke GL, Webber LS, et al Relation of obesity to clustering of cardiovascular disease risk factors in children and young adults The Bogalusa Heart Study Am J Epidemiol 1987;125(3):364–372 178 Goodman E, Daniels SR, Meigs JB, Dolan LM  ... familial cardiovascular mortality in obese schoolchildren: the Muscatine Ponderosity Family Study Pediatrics 1992;89(2):262–268 173 Sinaiko AR, Donahue RP, Jacobs DR Jr, Prineas RJ Relation of weight and rate of increase in... Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study Pediatrics 2007;120(2):340–345 175 Grundy SM, Cleeman JI, Daniels SR, et al Diagnosis and management of the metabolic